Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489362 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL489361 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL19942939 | 0.90 | HSD17B10 (0.48) | HSD17B10HPGDATMSMN1; SMN2 | |
| SCHEMBL19943206 | 0.90 | HSD17B10 (0.48) | HSD17B10HPGDATMSMN1; SMN2 | |
| SCHEMBL17001784 | 0.90 | HSD17B10 (0.48) | HSD17B10HPGDATMSMN1; SMN2 | |
| SCHEMBL5781752 | 0.87 | NR1H2 (0.36) | HSD17B10ATM | |
| SCHEMBL5781753 | 0.87 | NR1H2 (0.36) | HSD17B10ATM | |
| SCHEMBL24121385 | 0.84 | ATM (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL71904 | 0.84 | NR1H2 (0.45) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL8073389 | 0.84 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | HSD17B10 2950/4885CHRM2 136/4885CHRM1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.